HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ZED1227

Also Known As:

2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-,methyl ester, (2E,6S)-

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - ZED1227: 3
  - Pyridines: 88
    - ZED1227: 3

Experts

1.	Aeschlimann, Daniel: 1 article (01/2022)
2.	Büchold, Christian: 1 article (01/2022)
3.	Gerlach, Uwe: 1 article (01/2022)
4.	Heil, Andreas: 1 article (01/2022)
5.	Hils, Martin: 1 article (01/2022)
6.	Pasternack, Ralf: 1 article (01/2022)
7.	Pelzer, Christiane: 1 article (01/2022)
8.	Weber, Johannes: 1 article (01/2022)
9.	Biedermann, Luc: 1 article (01/2021)
10.	Byrnes, Valerie: 1 article (01/2021)

Related Diseases

1.

Celiac Disease (Celiac Sprue)

01/01/2022 - "Recently, in an exploratory proof-of-concept study, ZED1227 administration clinically validated TG2 as a "druggable" target in celiac disease. "
01/01/2021 - "In this preliminary trial, treatment with ZED1227 attenuated gluten-induced duodenal mucosal damage in patients with celiac disease. "
01/01/2022 - "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease."
01/01/2021 - "In a proof-of-concept trial, we assessed the efficacy and safety of a 6-week treatment with ZED1227, a selective oral transglutaminase 2 inhibitor, at three dose levels as compared with placebo, in adults with well-controlled celiac disease who underwent a daily gluten challenge. "
06/28/2023 - "The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment."

Related Drugs and Biologics

1.	Protein Glutamine gamma Glutamyltransferase 2
2.	Glutens (Glutelin)